

**MEĐUNARODNI SIMPOZIJUM O
KARCINOMU ŠTITASTE ŽLEZDE**

**INTERNATIONAL SYMPOSIUM ON
THYROID CARCINOMA**

Novi Sad April 6-7, 2023



Venue

**Amphitheater of Cinema Hall,
Institutes in Sremska Kamenica**



Organizers:
Faculty of Medicine, University of Novi Sad
&
Academy of Medical Sciences Serbian Medical Society



Scientific Committee

Prof Stanley Goldsmith, MD, ScD (Hon), DMed (Hon)
Professor Emeritus in Radiology,
Professor of Medicine, Weill Cornell Medicine, New York City, USA

Dr Katarina Nikoletic, MD, PhD
Vestre Viken HF, Drammen Hospital, Nuclearmedicine Department, Drammen, NORWAY

Prof dr Ralph McCready, MD, PhD
Hon Consultant Nuclear Medicine, Royal Sussex County Hospital Brighton, Brighton, UK

Prof Jean-Noel Talbot, MD, PhD
French National Institute for Radioactivity, Saclay, FRANCE

Prof Vladimir Obradovic, MD, PhD
Head of Board of Directors, Clinical Centre of Serbia, Belgrade, SERBIA

Organizing Committee

Prof Jasna Mihailovic, MD, PhD
Department of Nuclear Medicine, Faculty of Medicine, Novi Sad,
Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA

Assoc Prof Nataša Prvulovic-Bunovic, MD, PhD
Department of Nuclear Medicine, Faculty of Medicine, Novi Sad,
Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA

Dr Jelena Roganovic, MD
Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA

Marko Vasiljevic, Chief Technologist
Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA



Dear colleagues and guests,

It is my great pleasure to welcome you in the city of Novi Sad for attending the International Symposium on Thyroid Cancer.

The Meeting is organized by the Medical Faculty of Novi Sad and the Academy of Medical Sciences.

Management of patients with thyroid cancer has changed over the past years. Current recommendations and guidelines enable us to diagnose and treat the patients with new techniques and radiopharmaceuticals, improving compliance and effectiveness of treatment and improve patient clinical outcome.

Therefore, the scientific program of the symposium has been designed to cover a wide range of nuclear imaging modalities and therapies in thyroid cancer patients. We hope it will be interesting to the experts of nuclear medicine, oncology, and endocrinology.

Additionally, this meeting is intriguing and challenging for young nuclear medicine specialists and residents. Different specialists are invited to evaluate and learn about the role of nuclear medicine theragnostics imaging to diagnose and treat the thyroid cancer.

As the hosting city, city of Novi Sad has not been nicknamed the “Athens of Serbia” without a reason; its history as a vibrant, creative city continues nowadays through its recognized art galleries, rich musical events, and a vibe that is generally more liberal than that of other Serbian cities. Novi Sad was announced with two prestigious titles: European Youth Capital for the year 2019 and European Capital of Culture for the year 2021.

This meeting is a great opportunity for all of you to communicate with colleagues from different countries all over the world. I am sure it will result in creative exchange of ideas and future collaboration.

We look forward to welcoming you in our beautiful city of Novi Sad. Yours Sincerely

Prof. Jasna Mihailovic, MD, PhD
Chairman, Organizing Committee

A handwritten signature in cursive script that reads "Mihailovic Jasna".

SCIENTIFIC PROGRAM

Registration of the participants: Thursday April 6, 14-17h

15.00-16.30 Session 1: THYROID CANCER-GENETICS, HISTOLOGY AND SURGICAL TREATMENT

Moderators: Seza Gulec, Sabina Dizdarevic

15.00-15.15

Svetislav Tatic, MD, PhD, Prof, SERBIA

Thyroid Cancer-What is New in WHO Classification 2022?

15.15-15.30

Djuro Macut, MD, PhD, Prof, SERBIA

Medullary Thyroid Cancer – Diagnostic and Therapeutic Approach

15.30-15.45

Ivan Paunovic, MD, PhD, Prof, SERBIA

Modern Aspects of Surgical Management in Papillary Thyroid Cancer

15.45-16.00

Ivan Markovic, MD, PhD, Prof, SERBIA

Papillary Thyroid Microcarcinoma – Is It Minimal Disease?

16.00-16.15

Ivan Majdevac, MD, SERBIA

Surgical Approach in Positive Sentinel Node Biopsy in Medullary Thyroid Cancer

16.15-16.30

Discussion

16.30-17.00

Award “Ljubomir Stefanovic”

17.00-17.30

Visit of new unit of Department of Nuclear Medicine in “Kamenica 3”

17.30-18.00

Welcome Cocktail

18.00-20.00 Session 2: E-POSTER PRESENTATIONS: Physicians, Physicists, Radiochemists and Technologists

Moderators: Zeravica Radmila, Dragan Pucar

1. Teodor Sofiyanski, Milena Dimcheva, Sonya Sergieva; BULGARIA

Somatostatin Receptor-Targeted Radionuclide Therapy Possible Application in Selected Patients With Thyroid Cancer – Clinical Case Report

2. Starcevic I, Mihailovic J, Roganovic J, Simic A; SERBIA Is There a Role of

Preoperative Thyroglobulin Measurement in the Diagnostic Algorithm of Thyroid Nodules?

3. Roganovic J, Starcevic I, Mihailovic J, Prvulovic-Bunovic N; SERBIA

Multiple Primary Tumors - A Case Report

4. Jeremic M, Matovic M; SERBIA

Verification of the Radioiodine Uptake Test

5. Popovic Krmeta M, Bazic Djorovic B, Stojiljkovic M, Sobic Saranovic D, Mijatovic Teodorovic L; SERBIA

A Case Report of Rare Hyperfunctioning Metastatic Thyroid Carcinoma

6. *Novakovic T, Ivkovic-Kapicl T, Vasiljevic T; SERBIA*
Medullary Carcinoma of the Thyroid Gland: A 5-Year Institutional Experience
7. *Petrovic J, Stojiljkovic M, Sobic Saranovic D, Artiko V; SERBIA*
Role of FDG PET/CT in Suspected Recurrent Medullary Cancer
8. *Petrović J, Veljković M, Petrović N, Šobić Šaranović D, Artiko; SERBIA*
Diagnosis of Residual and Recurrent Disease in the Setting of Elevated Serum Calcitonin Levels After Surgical Resection of Medullary Thyroid Carcinoma using SPECT and SPECT/CT Tc-99m Tektrotyd Scintigraphy
9. *Shurinov AYu, Krylov VV, Borodavina EV, Severskaya NV, Sigov MA, Bespalov PD; RUSSIA*
Efficiency of Radioiodine Remnant Ablation in Cases of Locally Differentiated Thyroid Cancer. Original Clinical Trial.
10. *Simic A, Mihailovic J, Roganovic J; SERBIA*
Association of Differentiated Thyroid Cancer and Bilateral Ductal Invasive Breast Cancer – Case Report
11. *Stojanovic D, Lucic S, Peter A, Cimbajjevic V; SERBIA*
Anaplastic Thyroid Carcinoma With Initial Features Mimicking Subacute Thyroiditis: A Case Report
12. *Stojanovic D, Lucic S, Peter A, Cimbajjevic V; SERBIA*
Eleveted Values of Calcitonin in a Patient With Thyroid Nodules are not Pathognomonic Sign of Medullary Thyroid Carcinoma
13. *Mirkovic M, Radovic M, Milanovic Z, Stankovic D, Peric M, Vukadinovic A, Laban O, Jankovic D, Vranjes Duric S; SERBIA*
Production and Quality Assurance of I-131 Capsules in the Laboratory for Radioisotopes of the Vinča Institute of Nuclear Sciences
14. *Stankovic M; SERBIA*
**Posttreatment I-131 WBS in Differentiated Thyroid Cancer:
Is Nuclear Medicine Technologist Able to Detect Artifacts and Pitfalls?**
15. *Hadzic K; SERBIA*
**The Role of Nuclear Medicine Technologist in F-18 FDG-PET/CT Imaging –
How to Avoid Pitfalls and Artifacts?**
16. *Filko M; SERBIA*
The Role of Nuclear Medical Technologist in PRRT Treatment
17. *Slepcev Tamburic M; SERBIA*
**The Role of Nuclear Medicine Technologist in the Application of Radioiodine Therapy
of Differentiated Thyroid Cancer**
18. *Vasiljevic M; SERBIA*
**What is the Role of Nuclear Medicine Technologist in F-18 FDG-PET/CT Imaging of Oncologic
Patients?**
19. *Rakic M; SERBIA Tc-99m*
Tektrotyd Scintigraphy - Nuclear Medicine Technologist Aspect

Registration of the participants: Friday April 7, 8,30-12h

9.00-11.15 Session 3: RAI THERANOSTICS AND DIFFERENT GUIDELINES FOR DTC MANAGEMENT

Moderators: Jasna Mihailovic, Andrej Shurinov

09.00-09.30

Seza Gulec, MD, Prof, USA

RAI Theranostics

09.30-10.00

Luca Giovanella, MD, PhD, Prof, SWITZERLAND

Joint SNMMI/EANM Guidelines: Recognizing the Differences to Take Better Care

10.00-10.30

Sabina Dizdarevic, MD, PhD, Prof, UK

Multidisciplinary Team Working and British Thyroid Association (BTA) Guidelines and Dynamic Risk Stratification in the Management of Thyroid Cancer

10.30-11.00

Milos Zarkovic, MD, PhD, Prof, SERBIA

ETA Statement and Guidelines on Postsurgical Radioiodine Treatment

11.00-11.15

Discussion

11.15-11.45

Coffee break

11.45-13.40 Session 4: TREATMENT APPROACHES FOR IODINE-AVID AND IODINE-REFRACTORY DTC-EXPERIENCES FROM DIFFERENT COUNTRIES

Moderators: Milovan Matovic, Raluca Mititelu

11.45-12.05

Andrej Shurinov, MD, RUSSIA

Radioiodine Treatment of DTC-Russian Experience

12.05-12.25

Tamara Geliashvili, MD, PhD, RUSSIA

Treatment of DTC Bone Oligometastases: Review of the Literature and Own Experience

12.25-12.45

Jasna Mihailovic, MD, PhD, Prof, SERBIA

Paradigm of DTC Management – Serbian Experience

12.45-13.05

Levent Kabasakal, MD, PhD, Prof, TURKEY

Dosimetric Approaches for the Ablation Therapy of Well DTC

13.05-13.25

Marina Vljajkovic, MD, PhD, Prof, SERBIA

Treatment Approaches to Radioactive Iodine-Refractory DTC

13.25-13.40

Discussion

13.40-14.30

Lunch

14.30-16.35 Session 5: THYROID CANCER-FUNCTIONAL AND METABOLIC IMAGING IN DTC

Moderators: Tamara Geliashvili, Levent Kabasakal

14.30-15.00

Douglas Van Nostrand, MD, Prof, USA

Enhanced Techniques to Increase the Utility of Radioiodine Imaging in Patients With DTC

15.00-15.20

Natasa Prvulovic-Bunovic, MD, PhD, Assoc Prof, SERBIA

Role of Ultrasound in Detection of Loco-Regional Recurrence in DTC

15.20-15.40

Sonya Sergieva, MD, PhD, Prof, BULGARIA

131-I SPECT/CT Imaging in DTC

15.40-16.00

Raluca Mititelu, MD, PhD, Prof, ROMANIA

The Role of F-18 FDG-PET/CT in the Management of Recurrent DTC

16.00-16.20

Paolo Castellucci, MD, Prof, ITALY

The Usefulness of Non-FDG Tracers in Thyroid Cancer

16.20-16.35

Discussion

16.35-16.50

Coffee break

16.50-18.00 Session 6: MEDULLARY THYROID CANCER-IMAGING AND TREATMENT

Moderators: Sonya Sergieva, Paolo Castellucci

16.50-17.10

Irene Virgolini, MD, PhD, Prof, AUSTRIA

New PET/CT Radiotracers for Diagnostics of Medullary Thyroid Cancer

17.10-17.30

Rosy Krasteva, MD, PhD, Prof, BULGARIA

Targeted Therapy for Thyroid Carcinoma

17.30-17.50

Branislava Radovic, MD, PhD, Assist Prof, SERBIA

Role of Nuclear Medicine in Medullary Thyroid Carcinoma Management

17.50-18.00

Discussion

18.00

Closing of the Symposium

Zlatni sponzor:




M A G N A
P H A R M A C I A



Distributor
GE Healthcare

Sponzori:



ИНСТИТУТ "ВИНЧА"
СПОЉНОТРГОВИНСКИ ПРОМЕТ

